About the Client
The client is an American multinational company headquartered in New York City, and one of the world’s largest pharmaceutical companies in the world, consistently ranking on the Fortune 500 list of the largest U.S. corporations.
The client faced a critical challenge in accurately identifying diseases from X-ray reports. With an extensive database of X-ray images from patients worldwide, they realized the need to harness the power of cutting-edge technology to enhance disease detection capabilities. The sheer volume of data presented a formidable task for medical professionals to efficiently analyze and diagnose illnesses. They sought to build advanced algorithms to enhance disease detection capabilities. Their key objectives included:
Brillio assisted the client throughout the implementation in addressing their challenges and delivered an innovative and scalable solution. Brillio’s expert team then undertook meticulous data pre-processing, and, drawing on the latest advancements in deep learning, Brillio’s AI experts developed three powerful candidate classification models based on DenseNet and CNN architectures with remarkable proficiency in detecting various diseases from X-ray reports. The solution involved the following steps:
With Brillio’s expertise, the client successfully leveraged AI to automate disease discovery from X-ray reports. The implementation of deep neural networks and the seamless integration with model output allowed for accurate disease detection, automated reporting, and scalability, revolutionizing the way diseases are diagnosed and treated. The solution stands as a testament to the potential of AI in revolutionizing healthcare and streamlining critical processes for better patient outcomes.
82-87% Disease Detection Accuracy
70% Cost Reduction in Detecting 15 Diseases
85% Reduced Time to Detect Diseases